Close

Pfizer's (PFE) Palbociclib Has $5 Billion Potential

Go back to Pfizer's (PFE) Palbociclib Has $5 Billion Potential

Pfizer's (PFE) Palbociclib Receives Breakthrough Therapy Designation from FDA

April 10, 2013 8:03 AM EDT

Pfizer Inc. (NYSE: PFE) announced today its investigational compound palbociclib (PD-0332991), an oral and selective inhibitor of cyclin dependent kinases (CDK) 4 and 6, has received Breakthrough Therapy designation by the United States Food and Drug Administration (FDA) for the potential treatment of patients with breast cancer.

Enacted as part of... More